Letter to the editor
The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction

https://doi.org/10.1016/j.jaci.2012.02.051Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (19)

  • Work Group Report: Perspectives in Diagnosis and Management of Exercise-Induced Bronchoconstriction in Athletes

    2020, Journal of Allergy and Clinical Immunology: In Practice
    Citation Excerpt :

    As with SABAs, tolerance can also develop with long-acting β2-agonists.5 Leukotriene receptor antagonists (montelukast) can be administered daily for prophylaxis, as an add-on therapy to inhaled steroids, or given 1 to 2 hours before exercise, which has shown efficacy in preventing EIB for up to 12 to 24 hours.79-83 Other leukotriene receptor antagonists including zafirlukast and zileuton, a 5-lipoxygenase inhibitor, have also been shown to be effective in EIB.

  • Cough in exercise and athletes

    2019, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    If low doses of ICS do not achieve asthma control, the addition of another controller drug should be considered, such as a long-acting inhaled β2-agonist or a leukotriene-receptor antagonist (LTRA). This last can help reduce EIB [96] and has protective effects against the bronchoconstriction caused by exposure to pollutants [97]. Cromolyn sodium and nedocromil sodium protect against EIB, but inhaled β2-agonists are more effective and can be used 5–10 min before exercise.

  • Exercise-induced bronchoconstriction update—2016

    2016, Journal of Allergy and Clinical Immunology
  • Role of Cells and Mediators in Exercise-Induced Bronchoconstriction

    2013, Immunology and Allergy Clinics of North America
    Citation Excerpt :

    These results clearly demonstrate a role for CysLTs in the pathogenesis of EIB but also indicate that the protection from EIB is incomplete, suggesting that mediators other than the CysLTs may play a significant role and that the loss of bronchoprotective mediators may be important. A recent study found that an ICS added to a CysLT1 antagonist had improved efficacy over treatment with either an ICS or CysLT1 antagonist alone.53 Mast cells and eosinophils are strongly implicated as the cellular sources of CysLTs and other eicosanoids such as PGD2 in EIB.

View all citing articles on Scopus

This study was sponsored by Merck Frosst.

Disclosure of potential conflict of interest: P. M. O'Byrne has served on advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer, Merck, and Almiral; has received speakers' honoraria from AstraZeneca; and has received research support from AstraZeneca, Asmacure, Genentech, Amgen, ONO, and AIM. The rest of the authors declare that they have no relevant conflicts of interest.

View full text